Jeffrey Stark, MD, vice president and head of medical immunology at UCB, analyzes the Bimzelx Navigate program, a comprehensive support system developed to empower patients prescribed bimekizumab ...
Brussels (Belgium), March 7, 2025 – 14:00 (CET) – UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX ® (bimekizumab-bkzx) in moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback